In the first of a series of interviews, our CEO Dennis Benkmann sat down with Celean Camp, CEO of FRAME – Fund for the Replacement of Animals in Medical Experiments, to delve into the transformative strides made in non-animal testing throughout 2023.
Key highlights include substantial progress in the EU towards phasing out animal testing and the FDA Modernization Act, opening new avenues for utilizing non-animal data. The broader conversation also touched upon the shifting dynamics in the discourse around animal use in research and testing.
Why does this matter? It goes beyond industry advancements. It's about collectively redefining our approach to research and embracing alternatives that are not just effective but ethical. As part of our commitment, our own brand cellQART® is at the forefront, developing products aimed at enabling in vitro testing through advanced cell culture applications.
Stay tuned for more insights as we continue our interview series with part two next week.
